Merck said the strong growth was due in part to this year's measles outbreak, which was the largest in the U.S. since 1992
A nurse holds up a one dose bottle and a prepared syringe of measles, mumps and rubella virus vaccine made by Merck at the Utah County Health Department on April 29, 2019 in Provo, Utah.said Tuesday that high consumer demand for its measles vaccines, amid the largest U.S. outbreak in decades, help boost sales in its second quarter.
Sales of children vaccines, which includes the New Jersey-based company's MMR vaccine for measles, mumps and rubella, jumped 58% year-over-year to $675 million, Merck announced in its second-quarter earnings report Tuesday. Merck, who is the sole U.S. supplier of measles vaccines, said the strong growth was due in part to this year's measles outbreak, which was the largest in the U.S. since 1992.
"There was some buying to the private sector within the U.S. this quarter based on some of the measles outbreaks that you read in the news," Merck Chief Commercial Officer Frank Clyburn said in a post-earnings conference call with investors. "And we do believe that we'll continue to see growth for our pediatric vaccines going forward."and revenue that easily beat Wall Street's estimates.
Source: News Formal (newsformal.com)
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: CNBC - 🏆 12. / 72 Read more »
Source: MSNBC - 🏆 469. / 51 Read more »
Source: Reuters - 🏆 2. / 97 Read more »
Source: Reuters - 🏆 2. / 97 Read more »
Source: Reuters - 🏆 2. / 97 Read more »